Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12918469 | 0.88 | TDP1 (0.50) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| Ethylene Glycol SCHEMBL11597315 | 0.83 | TDP1 (0.46) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL31519170 | 0.83 | ALDH1A1 (0.42) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL2349139 | 0.81 | ALDH1A1 (0.41) | TDP1ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL31519162 | 0.81 | TDP1 (0.36) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL13886570 | 0.80 | ALDH1A1 (0.54) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL31519174 | 0.80 | TDP1 (0.35) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL1079198 | 0.79 | TDP1 (0.56) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL2930338 | 0.78 | ALDH1A1 (0.52) | TDP1ALDH1A1LMNAHSD17B10TSHR | |
| SCHEMBL11720069 | 0.77 | TSHR (0.43) | TDP1ALDH1A1LMNATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380781-A | Preparation method of 2-cyano-8-nitro-4-oxo-4H-1-benzopyran | 南京焕然生物科技有限公司 | 2022-04-22 | — | — | CN | claimed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | claimed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | claimed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | claimed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | claimed |
| CN-117203181-A | Halogenated cyclopropanation process | 科迪华农业科技有限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230288807-A1 | PHOTORESIST, METHOD OF MANUFACTURING A SEMICONDUCTOR DEVICE AND METHOD OF EXTREME ULTRAVIOLET LITHOGRAPHY | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2023-09-14 | — | — | US | disclosed |
| CN-115666546-A | Enteral oxidation therapy | 卢普奥克西治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115066445-A | Polyisocyanate formulations | 科思创德国股份有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-114380781-A | Preparation method of 2-cyano-8-nitro-4-oxo-4H-1-benzopyran | 南京焕然生物科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-113825398-A | Pyridazinone compounds and herbicides | 日产化学株式会社 | 2021-12-21 | — | — | CN | disclosed |
| WO-2020020377-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | 北京加科思新药研发有限公司 | 2020-01-30 | — | — | WO | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2324041-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Corp. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010019511-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| CN-1213457-A | Method and apparatus for babricating silion dioxide and silicon glass layer in integrated circuits | SYMETRIX CORP (US) | 1999-04-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | TDP1 3195/4885ALDH1A1 3493/4885LMNA 3377/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | TDP1 630/4885ALDH1A1 14/4885LMNA 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.